

## P2X<sub>7</sub> receptors in cerebral ischemia

Hui-Yu Bai, Ai-Ping Li

*Department of Physiology, Dalian Medical University, Dalian 116044, China*

Corresponding author: Ai-Ping Li. E-mail: [li.ap@126.com](mailto:li.ap@126.com)

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2013

Cerebral ischemia is one of the most common diseases resulting in death and disability in aged people. It leads immediately to rapid energy failure, ATP depletion, and ionic imbalance, which increase extracellular ATP levels and accordingly activate P2X<sub>7</sub> receptors. These receptors are ATP-gated cation channels and widely distributed in nerve cells, especially in the immunocompetent cells of the brain. Currently, interest in the roles of P2X<sub>7</sub> receptors in ischemic brain injury is growing. In this review, we discuss recent research progress on the actions of P2X<sub>7</sub> receptors, their possible mechanisms in cerebral ischemia, and the potential therapeutic value of P2X<sub>7</sub> receptor antagonists which may provide a new target both for clinical and for research purposes.

**Keywords:** P2X<sub>7</sub> receptor; cerebral ischemia; neurotoxicity; calcium overload; neuroinflammation; neurotransmitter; receptor antagonist

### Introduction

Cerebral ischemia remains a major cause of morbidity and mortality worldwide in aged people and affects millions every year. Immediately after ischemia, the cerebral blood flow dramatically decreases in the ischemic core, leading to rapid energy failure, ATP depletion, ionic imbalance, and neuronal death<sup>[1]</sup>. The cells in the penumbra (tissues surrounding the ischemic core), however, can retain their activity for a prolonged period. The neurodegenerative episodes and neuronal loss gradually expand from the ischemic core to the penumbra in the following several days. Therefore, effective interventions in this period are essential.

Extracellular ATP is an important signaling molecule mediating interactions among various types of cells in the central nervous system (CNS)<sup>[2]</sup>. It acts on cell-surface P2 purinoceptors and serves as a neurotransmitter, neuromodulator, and trophic factor under physiological conditions. On the other hand, pathological events such as mechanical or metabolic stress, inflammation, cellular injury, or changes in the ionic environment are all known to powerfully stimulate ATP release. This results in an

ATP-rich extracellular environment leading to widespread activation of receptors on astrocytes and microglia and boosting diverse pathological cascades, such as glutamatergic excitotoxicity, and oxidative damage, as well as IL-1 $\beta$  and other cytokine-mediated signaling<sup>[3]</sup>. P2 receptors are classified into two subfamilies, P2X and P2Y. ATP couples to the ligand-gated P2X ion channel receptors and mediates fast excitatory neurotransmission, while ATP binds to the GTP-binding P2Y receptors to evoke slow excitatory responses. Seven distinct ionotropic P2X (P2X<sub>1-7</sub>) and eight distinct metabotropic P2Y receptor subunits (P2Y<sub>1,2,4,6,11-14</sub>), classified by electrophysiological properties and their amino-acid sequence homology, have been cloned from mammals<sup>[4]</sup>.

P2X receptors are widely distributed in excitable and non-excitable cells of vertebrates. They play key roles in regulating afferent signaling (including pain), renal blood flow, the vascular endothelium, inflammatory responses, tumorigenesis, CNS injury, and embryonic development<sup>[5, 6]</sup>. Of the P2X family, the P2X<sub>7</sub> receptor (P2X<sub>7</sub>R) has specific structural and pharmacological features and may play a prominent role in the progression of various neurological disorders, such as cerebral ischemic injury (stroke),

Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, neuropathic pain and depression<sup>[3, 7, 8]</sup>. In the past few years, the potential role of this receptor in neuronal functions during cerebral ischemic stroke has received considerable attention.

Nevertheless, a major debate has emerged on the roles of activated P2X<sub>7</sub>Rs in animal and cellular models of this disorder. Most indicate that up-regulation or over-activation of P2X<sub>7</sub>Rs aggravate the brain tissue damage and sensorimotor deficit through several mechanisms such as Ca<sup>2+</sup> overload which induces excitotoxic neuronal death or apoptosis, and receptor antagonists play a protective role<sup>[1, 4, 9-12]</sup>. However, a few reports are contradictory<sup>[13, 14]</sup>. In the following we thus review the unique properties of P2X<sub>7</sub>Rs compared to other P2X receptor family members, the possible mechanisms of their actions in cerebral ischemia, and the potential therapeutic exploitation of P2X<sub>7</sub>R antagonists.

### **P2X<sub>7</sub> Receptors and Their Unusual Properties Compared with Other P2X Family Receptors**

The P2X<sub>7</sub>R was first discovered by Buisman in 1988 and Gordon named it the P2z receptor<sup>[15]</sup> meaning "cell death receptor"<sup>[3]</sup> or "suicide receptor"<sup>[5]</sup> because its prolonged activation leads to cellular death. In 1996, the P2X<sub>7</sub>R was first cloned from a rat brain cDNA library and classified as a member of the P2X receptor family<sup>[7]</sup>.

P2X<sub>7</sub>Rs have several properties that set them apart from other members of the P2X receptor family. First, the P2X<sub>7</sub>R is 595 amino-acids long, having 35–40% homology with the other six members of the family<sup>[3]</sup>. Only the P2X<sub>7</sub>R does not heterotrimerize with other P2X subunits. However, it was shown recently that P2X<sub>7</sub>R subunits functionally interact with P2X<sub>4</sub> subunits in macrophages. The heteromeric P2X<sub>4</sub>/P2X<sub>7</sub> receptor appears to have the pharmacological properties of both of the homomeric receptor subtypes<sup>[10]</sup>. Second, except for two transmembrane domains (M1 and M2) and a large extracellular loop containing the ATP-binding site<sup>[16]</sup>, the P2X<sub>7</sub>R has a unique structural feature: its intracellular carboxy terminal domain is much longer (239 amino-acids) than those of the other P2X receptor subunits (27–129 amino-acids). This long C-terminal tail can combine with many downstream proteins and lipids in the cytoplasm<sup>[7]</sup>,

and this is associated with unique functions as well as cellular localization<sup>[17]</sup>. Third, in contrast to other P2X receptors, the P2X<sub>7</sub>R has a lower affinity for ATP<sup>[18]</sup>, and only relatively higher concentrations of extracellular ATP (millimolar range) can activate P2X<sub>7</sub>Rs relative to other P2X receptors (micromolar range)<sup>[7, 10, 19]</sup>. Last but not least, P2X<sub>7</sub>Rs are bifunctional because they have two states, cation channels and plasma membrane pores<sup>[20]</sup>. When stimulated by lower concentrations of ATP, P2X<sub>7</sub>Rs are mildly activated and function as small cation channels with a permeability significantly higher to Ca<sup>2+</sup> than to Na<sup>+</sup> and K<sup>+</sup><sup>[9]</sup>. Repetitive or prolonged exposure to higher concentrations of ATP elicits progressive dilation of the receptor cation channel, which finally forms a large irreversible and nonselective transmembrane pore permeable to macromolecules up to 900 Da in size<sup>[1, 3, 21]</sup>. This promotes actin disaggregation, rapid cytoskeletal rearrangement, membrane blebbing, cytokine release, and finally apoptosis and cell death<sup>[9]</sup>. Wang *et al.*<sup>[22]</sup> reported that spinal cord injury is associated with high ATP release that lasts for at least 6 h after the initial injury. Exposure of P2X<sub>7</sub>Rs on spinal cord neurons to ATP leads to high-frequency spiking, an irreversible increase in cytosolic Ca<sup>2+</sup> and cell death, while P2X<sub>7</sub>R antagonists inhibit this process and facilitate functional recovery. Another study indicated that the ATP concentration in the striatum of normoxic rats is 3.10 ± 0.34 nmol/L. During 220 min after middle cerebral artery occlusion (MCAO), extracellular ATP levels significantly increase to 5.90 ± 0.61 nmol/L<sup>[23]</sup>. In addition, stimulation of P2X<sub>7</sub>Rs with high concentrations of ATP has dramatic cytotoxic actions in many neurodegenerative processes<sup>[24]</sup>.

### **Activation of P2X<sub>7</sub> Receptors in Ischemic Brain Injury**

#### **P2X<sub>7</sub> Receptor Expression in the CNS under Physiological Conditions**

Under normal conditions, P2X<sub>7</sub>Rs are widespread on the membranes of neurons, astrocytes, microglia, oligodendrocytes, and oligodendrocyte precursor cells, as well as Schwann cells<sup>[14, 25-27]</sup>, unlike the localization of P2X<sub>1-6</sub> receptor subtypes, which is mainly on the membranes of neurons<sup>[28]</sup>. They are especially abundant on microglia that are in a physiologically resting state,

display ramified morphology with numerous branching processes<sup>[20]</sup>, and play protective roles such as host defense and tissue repair<sup>[28]</sup> against neuronal damage<sup>[29]</sup>, suggesting that P2X<sub>7</sub>Rs are involved in immune functions and inflammatory responses<sup>[13]</sup>. The cellular localization of P2X<sub>7</sub>Rs in the CNS remains controversial. Yu *et al.* described the precise distribution of P2X<sub>7</sub> mRNA in the rat brain using isotopic *in situ* hybridization. Small P2X<sub>7</sub>-positive glial-like cells are sporadically scattered in almost all areas of the brain<sup>[30]</sup>. In neurons, P2X<sub>7</sub>Rs are primarily distributed on presynaptic terminals in the medulla oblongata and spinal cord, excitatory nerve terminals of CA1, CA3, the dentate gyrus and mossy fibers of the hippocampus, cortical synaptosomes, neuronal cell bodies of the medulla oblongata and hippocampus<sup>[1]</sup> and the nuclear envelope of postsynaptic neurons<sup>[11]</sup>. P2X<sub>7</sub>Rs on the presynaptic membrane might serve as sensors of neuronal activity and extracellular ATP release, whereas the receptors on the nuclear envelope, regulated by cytoplasmic ATP, may be a mechanism of changing gene expression<sup>[31]</sup>.

### **Altered Expression and Function of P2X<sub>7</sub> Receptors in Cerebral Ischemia**

Many studies have suggested that, after cerebral ischemia, activated P2X<sub>7</sub>Rs are expressed predominantly on activated microglia in the penumbra and on reactive microglia. Reactive microglia are in a state intermediate between activation and rest. They are at rest in shape but have positive P2X<sub>7</sub>R immunoreactivity in remote projection areas such as the cingulate and medial frontal cortex and the synaptic terminals of neurons<sup>[4, 13]</sup>. Activation of P2X<sub>7</sub>Rs contributes to post-anoxic depolarization and neuronal demise following ischemia<sup>[9]</sup>.

Oxygen/glucose deprivation (OGD) in the *ex vivo* model of organotypic hippocampal slice cultures rapidly and transiently up-regulates P2X<sub>7</sub>Rs in a time-dependent manner in the parallel fibers of the pyramidal cell layer in CA1 and CA2<sup>[11]</sup>. They directly participate in the metabolic impairment. OGD in mixed astrocytic/neuronal cultures selectively up-regulates P2X<sub>7</sub>R immunoreactivity in the plasma membrane of neurons, but not astrocytes, 12 h after ischemia<sup>[25]</sup>. Post-ischemic, time-dependent up-regulation of the P2X<sub>7</sub>R subtype on neurons and microglia in the MCAO model might be involved in neuronal apoptosis

and tissue damage, suggesting a role of this receptor in the pathophysiology of cerebral ischemia *in vivo*<sup>[1, 4]</sup>. Besides, a transient and significant enhancement in P2X<sub>7</sub> protein expression was reported to occur immediately after asphyxia in a rat model of intrauterine asphyxia<sup>[32]</sup>.

However, inconsistent with most reports that P2X<sub>7</sub>R expression is increased in response to OGD *in vitro* or MCAO *in vivo*, Wang *et al.* showed decreased expression of P2X<sub>7</sub>Rs in cultured oligodendrocyte precursor cells, the predominant oligodendrocyte-lineage stage in the cerebral hemispheres of the neonatal rat, after exposure to OGD for 2 h *in vitro*, and in a neonatal hypoxic-ischemic injury model in 3-day-old rats<sup>[14]</sup>. More recently, Zeng *et al.* reported that OGD decreases P2X<sub>7</sub>R expression and modulates GSK-3 $\beta$  phosphorylation in radial glial clone L2.3 cells, and BzATP (a selective agonist of the P2X<sub>7</sub>R) induces L2.3 cell death in a dose- and time-dependent manner<sup>[27]</sup>. However, Lee reported that in a rat model of anoxia-induced brain ischemia and reperfusion (I/R) injury, the whole brain P2X<sub>7</sub>R expression is unchanged at 6 h after anoxia<sup>[33]</sup>. The differences in the maturation status of brain tissue, and the manner and distribution of hypoxic-ischemic damage between the perinatal and adult brain might explain these discrepancies. The P2X<sub>7</sub>R-containing cells are lost in response to ischemia, which limits the detrimental consequences of post-ischemic brain injury. Depending on the diverse conditions of a given study, P2X<sub>7</sub>Rs may increase, decrease, or even fail to alter the infarct size<sup>[1]</sup>. Further, polymorphisms of the P2X<sub>7</sub>R gene might yield nonfunctional receptor protein and point mutations might cause trafficking defects or impaired function.

Although most studies demonstrated that blocking the P2X<sub>7</sub>Rs improves the neuronal injury *in vivo* and *in vitro*<sup>[22, 34]</sup>, Le Feuvre suggested that neither the knockout of P2X<sub>7</sub>Rs nor P2X<sub>7</sub>R antagonists affect the infarct volume in MCAO and in glutamate toxicity<sup>[12]</sup>. This may be explained by the activation of alternative compensatory pathways and thus suggests that the simple genetic deletion of P2X<sub>7</sub>Rs might not be the right model to investigate their roles<sup>[3]</sup>. So far, little has been done to study P2X<sub>7</sub> knockout in ischemia, and further studies are needed to elucidate the exact effects and specific mechanisms underlying the P2X<sub>7</sub>R knockout genotype in cerebral ischemia.

## Possible Mechanisms of Action of Activated P2X<sub>7</sub> Receptors after Cerebral Ischemia

### Activated P2X<sub>7</sub> Receptors Induce Ca<sup>2+</sup> Overload Leading to Cell Death

Cerebral ischemia induces excessive ATP release into the extracellular space from the cytoplasm of damaged and dying cells due to nucleic acid degradation and membrane permeability<sup>[1, 35]</sup>. There are several possible modes of ATP release: (1) damaged neurons are depolarized by the elevated extracellular K<sup>+</sup> due to impairment of the Na<sup>+</sup>-K<sup>+</sup> pump. ATP passively flows out along the electrochemical gradient through membrane channels of glial cells<sup>[23]</sup> or from the presynaptic vesicles exocytotically<sup>[36]</sup>; (2) organelles release ATP from astroglia in a Ca<sup>2+</sup>-independent manner *via* P2X<sub>7</sub>R channels<sup>[25, 36]</sup>; and (3) P2X<sub>7</sub>Rs on activated amoeboid microglia and reactive microglia amplify the ATP signal and trigger ATP release through an autocrine process<sup>[37, 38]</sup>. In short, cerebral ischemia results in a sustained progressive elevation of ATP levels in the penumbra<sup>[22, 23]</sup>.

The relatively high micromolar level of ATP in the extracellular space powerfully activates the P2X<sub>7</sub>Rs and leads to the formation of excitotoxic cytolytic pores<sup>[2, 39]</sup> and cell death.

Calcium overload is the prominent mechanism of P2X<sub>7</sub>R-mediated excitotoxic cell injury in stroke as well as *in vitro* models. Activated P2X<sub>7</sub>Rs contribute directly to a rapid increase of intracellular Ca<sup>2+</sup><sup>[40]</sup> (due to the massive influx of extracellular Ca<sup>2+</sup> *via* P2X<sub>7</sub>R membrane pores)<sup>[1, 41]</sup>. The resulting depolarization causes the secondary activation of voltage-gated Ca<sup>2+</sup> channels<sup>[41-43]</sup>, and intracellular Ca<sup>2+</sup> continuously increases. The high concentration of intracellular Ca<sup>2+</sup> activates nucleases and proteases (e.g., calpains) which eventually result in cell death<sup>[44]</sup>. Meanwhile, the mitochondrial matrix also takes Ca<sup>2+</sup> from the cytoplasm. When the Ca<sup>2+</sup> level in the mitochondrial matrix reaches a toxic threshold, the mitochondrial membrane potential collapses, the permeability transition pore opens, ions and solutes including Ca<sup>2+</sup> flow into the cytosol<sup>[45]</sup> and activate the apoptotic caspase enzyme system<sup>[17]</sup>. Despite the massive downstream effects of Ca<sup>2+</sup> overload, only a few intracellular signaling pathways have been described in detail. Currently, it has been shown that the ERK1/2 MAP kinase pathway contributes

to the pathological consequences of OGD in the cultured hippocampal slice<sup>[43]</sup>.

Pannexins are large membrane channels with broad expression throughout the body and have various functions. Pannexin-1 (Px1) is robustly expressed in the brain<sup>[47]</sup>. The opening of Px1 hemichannels is regulated by activated P2X<sub>7</sub>Rs under pathological conditions such as ischemia, and is responsible for the massive influx of Ca<sup>2+</sup> from the extracellular space. Iwabuchi *et al.*<sup>[46]</sup> reported recently that in cultured astrocytes, the suppression of P2X<sub>7</sub>R activity during OGD results in the opening of Px1 hemichannels, leading to enhanced ATP release and astrocytic damage, while the released ATP further activates local P2X<sub>7</sub>Rs, resulting in the closure of Px1 hemichannels, indicating the existence of a negative feedback loop. This negative feedback loop not only sustains astrocytic ionic homeostasis but also suppresses glutamate release *via* Px1 hemichannels.

### Activated P2X<sub>7</sub> Receptors Induce Neuroinflammation as a Double-edged Sword

Numerous studies indicate that P2X<sub>7</sub>Rs also participate in the regulation of neuroinflammation and neuroimmune reactions as an inflammatory mediator in the CNS<sup>[49-53]</sup>.

Microglia are the immune-competent cells in the CNS that participate in innate immune responses and communicate with other immunological cells *via* pro-inflammatory or anti-inflammatory cytokines, chemokines, and other bioactive substances. Their functions can be modulatory, protective or deleterious to the surrounding cells, including astrocytes and neurons<sup>[12]</sup>. Increased microglial activation and enhanced P2X<sub>7</sub>R expression are seen in ischemic stroke<sup>[1, 4, 9, 49, 53]</sup>. Monif *et al.* showed that P2X<sub>7</sub>R over-expression is sufficient to drive microglial activation, and ATP stimulation of P2X<sub>7</sub>Rs is required for microglial activation<sup>[16]</sup>. Lu *et al.* recently used a cerebral microemboli model and an *in vitro* culture system to study the roles of microglial activation and P2X<sub>7</sub>/FasL-Fas signaling following ischemic insult. They proposed an immunoreactive response loop in which microglia-derived FasL exaggerates P2X<sub>7</sub>-mediated microglial activation and triggers a vicious cycle of neuronal cell death in the ischemic context<sup>[47]</sup>.

However, in early stages of ischemic injury, microglial activation might be protective to the brain *via* P2X<sub>7</sub>Rs.

During this time, the low concentration of ATP acts as a chemoattractant for microglial recognition and migration<sup>[48]</sup>, directing them to the site of injury<sup>[49]</sup>. Like macrophages, activated microglia may remove potentially deleterious necrotic cell debris from the ischemic core, promote tissue repair, and thus contribute to neuroprotection<sup>[7]</sup>. On the other hand, activated microglia release neurotrophic factors *via* activated P2X<sub>7</sub>Rs and enhance neuronal survival<sup>[50]</sup>. P2X<sub>7</sub>R-activated microglia in neuron-microglia co-cultures protect neurons against glutamate toxicity primarily by releasing tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )<sup>[50]</sup>. Lack of microglia elevates the levels of several brain cytokines and chemokines such as IL-1 $\beta$ , TNF- $\alpha$ , CINC-1 and MCP-1, and increases the severity and volume of injury, indicating that microglia contribute to the endogenous protection against early injury after neonatal stroke<sup>[48]</sup>.

Nevertheless, in the later stages of cerebral ischemia, the high level of ATP stimulates microglial P2X<sub>7</sub>R over-expression (pore formation)<sup>[47]</sup> and leads to microglial activation, proliferation<sup>[51]</sup> and cell death. Over-activated microglia up-regulate the expression of their surface immunomodulatory proteins and release potentially neurotoxic pro-inflammatory cytokines such as IL-1 $\beta$ , IL-6 and TNF- $\alpha$ <sup>[16, 47]</sup>. These pro-inflammatory cytokines boost further microglial activation in an autocrine manner<sup>[16, 47]</sup> and induce secondary inflammatory injury in the penumbra<sup>[22, 50]</sup> which is an exaggerated and prolonged inflammatory response that results in continued neuronal cell death (not only damaged cells but also neighboring healthy cells)<sup>[10, 16]</sup>. Three models were recently proposed to explain the non-classical secretion of mature IL-1 $\beta$  following P2X<sub>7</sub>R activation<sup>[52]</sup>. The oldest and simplest model suggests that P2X<sub>7</sub>R-mediated cytolysis directly triggers rapid caspase-1 activation followed by the release of mature IL-1 $\beta$ <sup>[10, 53]</sup> depending on the K<sup>+</sup> and Ca<sup>2+</sup> efflux<sup>[54]</sup>. The other two models include the involvement of P2X<sub>7</sub>R-induced microvesicle shedding<sup>[24]</sup> or lysosome exocytosis from the plasma membrane into the extracellular medium<sup>[55]</sup>.

#### **Activated P2X<sub>7</sub> Receptors Modulate Neurotransmitter Release**

A series of functional data strongly supports the role of P2X<sub>7</sub>Rs in information processing in the normal and pathological nervous systems<sup>[25]</sup>. Several investigations suggest that after cerebral ischemic injury, the

extracellularly-accumulated ATP facilitates glutamate and gamma-aminobutyric acid (GABA) release from the terminals of neurons, astrocytes, and cortical microglia upon energy deprivation<sup>[3, 56]</sup>.

The up-regulation and extensive activation of P2X<sub>7</sub>Rs quickly inhibit glutamate uptake<sup>[57]</sup>, empty the cytoplasmic glutamate store, promote glutamate release and accumulation<sup>[42]</sup>, alter glutamate homeostasis, and trigger cell death<sup>[58]</sup>. Possibly, the activation of P2X<sub>7</sub>Rs simultaneously opens both cation channels permeable to large cations and anion channels permeable to organic anions such as L-glutamate and D-aspartate, mediating rapid non-vesicular glutamate release<sup>[26]</sup>. In a study of perinatal acute asphyxia, glutamate was verified to be released *via* the P2X<sub>7</sub>R channel<sup>[32]</sup>.

Although P2X<sub>7</sub>R channels are not selectively permeable to glutamate, the powerful driving force along the Na<sup>+</sup> and K<sup>+</sup> electrochemical gradient is responsible for significant glutamate efflux. Another underlying mechanism of glutamate release is that the insufficient energy supply and depolarization induced by ischemia cause a direct Na<sup>+</sup> influx, contributing to intracellular Na<sup>+</sup> overload which leads to the opening of voltage-sensitive Na<sup>+</sup> channels<sup>[42]</sup>. Consequently, endogenous over-activation of P2X<sub>7</sub>Rs participates in post-ischemic brain injury as an amplifying factor for glutamatergic excitotoxicity<sup>[42]</sup>. Excessive extracellular glutamate even forms a feedback loop and further down-regulates P2X<sub>7</sub>Rs<sup>[32]</sup>. It is noteworthy that this loop may represent a cellular effort to counteract and possibly halt the detrimental outcome of progressive neuronal damage.

GABA efflux is also dependent on the Na<sup>+</sup> and K<sup>+</sup> electrochemical gradients. Cerebral ischemia appears to markedly increase P2X<sub>7</sub>R-mediated GABA release, which may limit the severity of ischemic brain injury. Augmentation of the excitatory glutamatergic system facilitates the ischemia-induced neuronal damage, whereas augmentation of the inhibitory GABAergic system is neuroprotective. Therefore, the sum of these two opposing mechanisms may determine the infarct size<sup>[1]</sup>.

#### **Therapeutic Potential of P2X<sub>7</sub> Receptor Antagonists in Ischemic Brain Injury**

Since the up-regulation of the P2X<sub>7</sub>R system may stimulate

the process of cerebral ischemia, suppressing the deleterious roles of this receptor might be a therapeutic strategy for ameliorating the damage. Increasing numbers of P2X<sub>7</sub>R antagonists have been identified and optimized by pharmaceutical companies and academic groups, including KN-62, periodate-oxidized ATP (OxATP), Coomassie brilliant Blue G (BBG), RN-6189, A-740003, and A-438079<sup>[59]</sup>.

Among these, BBG and OxATP are the most widely used in recent studies of P2X<sub>7</sub>Rs. However, both suffer from relatively poor specificity<sup>[51]</sup>. OxATP has strong antagonistic effects not only on P2X<sub>7</sub>Rs, but also on other P2X receptors, and even P2Y receptors. It attenuates pro-inflammatory signaling by mechanisms independent of the expression or activation of P2 receptor subtypes<sup>[60]</sup>. This occurs in P2X<sub>7</sub>R-knockout mice, suggesting that one or more other P2 receptors are required<sup>[61]</sup>. BBG has nanomolar affinity for rat P2X<sub>7</sub>Rs and only micromolar affinity for some other P2X receptors.

Of the various P2X<sub>7</sub>R antagonists, BBG is the most potent, noncompetitive antagonist. BBG is derived from a blue food-dye, has been shown to be safe in healthy animals, and is approved for foodstuff use. It has low toxicity and can cross the blood-brain barrier<sup>[7]</sup>. The success of BBG in various animal studies suggests that P2X<sub>7</sub>Rs could serve as a therapeutic target for the treatment of neurodegenerative diseases.

Application of BBG reduces the electrical responses, Ca<sup>2+</sup> influx and neuronal death induced by OGD in neuron cultures and brain slices. Treatment with BBG remarkably reduces the extent of damage, inflammatory responses and learning memory deficits in MCAO and cerebral ischemia/reperfusion injury in the four-vessel occlusion rat model as well<sup>[9, 10, 51]</sup>. BBG drastically increases neuronal tolerance to mitochondrial dysfunction and glutamate release<sup>[10]</sup>. It locks the mitochondria and prevents neuronal death by blocking the mitochondrial Ca<sup>2+</sup> uptake and discharge of the mitochondrial membrane potential.

OxATP has been regarded as a selective P2X<sub>7</sub>R antagonist for a considerable time. It is a slowly-equilibrating and irreversible antagonist of P2X<sub>7</sub>Rs. OxATP has been widely used as a probe to identify P2X<sub>7</sub>R-mediated actions, especially in the immune system. It markedly attenuates the activation of microglia and interferes with inflammatory

signaling processes by decreasing the expression of pro-inflammatory cytokines<sup>[3]</sup>. Furthermore, OxATP blocks a sustained increase in [Ca<sup>2+</sup>]<sub>i</sub> through the P2X<sub>7</sub>R pores and then inhibits the activation of caspase and apoptotic cascades in lipopolysaccharide-induced inflammatory responses<sup>[20, 62]</sup>. The inhibition of P2X<sub>7</sub>R-mediated signals by OxATP limits post-ischemic inflammatory responses and confers neuroprotection<sup>[62]</sup>. OxATP prevents both the up-regulation of P2X<sub>7</sub>Rs and neuronal death evoked by their excitotoxic effect<sup>[3]</sup>, but only partially reduces or blocks the cellular damage in organotypic hippocampal cultures<sup>[11]</sup>.

Treatment with OxATP reduces the extent of brain damage in cerebral ischemia/reperfusion injury similar to BBG and A-438079<sup>[51]</sup>. However, other studies indicated that ischemic injury is exacerbated by OxATP in the rat MCAO model<sup>[13]</sup>. OxATP administration exacerbates the loss of MAP2-immunoreactivity in neurons in the cerebral cortex and striatum. This discrepancy might be explained by the possibility that P2X<sub>7</sub>Rs, P2X<sub>7</sub>-like receptors, and other unknown homologous receptors are expressed in the mouse brain, and ischemic injury may cause compensatory over-expression of P2X<sub>7</sub>-like receptor mRNAs and induce the opposite effects<sup>[13]</sup>.

KN-62 is another antagonist that may be useful for the pharmacological identification of P2X<sub>7</sub>Rs<sup>[3, 10]</sup>. It is also known as a selective CAM-kinase-II inhibitor, a selective antagonist of the human but not the rat P2X<sub>7</sub>R. KN-62 attenuates the elevation of neuronal nitric oxide synthase serine phosphorylation induced by ischemia in MCAO animals, and plays a neuroprotective role early in ischemia<sup>[63]</sup>.

3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl) methyl pyridine (A-438079) is a newly-discovered, selective antagonist of P2X<sub>7</sub>Rs in the brain. A-438079 significantly reduces P2X<sub>7</sub>R-mediated Ca<sup>2+</sup> responses and [<sup>3</sup>H] D-aspartate release mediated by BzATP stimulation in HEK293 cells. It also dose-dependently suppresses the production and release of p20-IL-1 $\beta$ , an unconventional 20-kDa form of IL-1 $\beta$ , induced by 4 mmol/L ATP in microglial cell culture<sup>[52]</sup>, indicating the efficacy of this drug in the brain. It is reported that this compound is essentially devoid of activity on other P2 receptors<sup>[64]</sup>.

Treatment with A-438079 correspondingly reduces the extent of brain damage in cerebral ischemia/reperfusion

injury<sup>[51]</sup>. Rats receiving 3 µg A-438079 have higher neuron survival rates and better motor performance than those receiving 1 µg OxATP. This may be due to the complex action of OxATP on other P2 receptors.

Compared with the other P2X receptor antagonists, PPADS (pyridoxal-phosphate-6- azophenyl-20, 40-disulphonic acid) is a more potent antagonist at P2 receptors. It decreases OGD-evoked glutamate efflux, attenuates glutamatergic excitotoxicity, and thus reduces neuronal death<sup>[34, 42, 65]</sup>. Therefore, this compound might provide a preferable approach to preventing the long-term ischemic brain injury evoked by glutamate release.

Reactive Blue 2 (RB2) is a sulfonic derivative anthraquinone and a non-selective antagonist of P2 receptors. It does not prevent, but rather promotes P2X<sub>7</sub>R expression in microglia and marks their transition from the resting to the reactive state within 24 h after MCAO<sup>[4]</sup>. This phenomenon occurs after brief treatment with RB2. Long-term RB2 treatment of rats eliminates the effect of P2X<sub>7</sub>R blockade in preventing microglial activation and ameliorating the ischemic brain injury in the penumbra. Nevertheless, in remote brain regions, it promotes the expression of P2X<sub>7</sub>Rs on reactive microglia, developing defensive and reparative processes<sup>[62]</sup>. Whether the neuroprotective action of RB2 is solely dependent on the modulation of P2X<sub>7</sub>Rs in microglia, or on additional P2 receptors is still unclear.

## Conclusion

After cerebral ischemia, the penumbra is damaged but cells within this area can be saved. Consequently, the functional loss associated with stroke can be limited. Strong stimulation of P2X<sub>7</sub>Rs, which is likely to involve large and nonselective pore formation, leads to cell death of both neurons and certain glial cells, especially microglia. Inhibition of P2X<sub>7</sub>R activation to reduce the excitotoxic effect of Ca<sup>2+</sup> overload, inflammation, and glutamate release would protect against neuronal death and suppress microglial activation.

So far, the physiological functions and the contribution of P2X<sub>7</sub>Rs in cerebral ischemic injury remain unclear, even though such information is essential for the evaluation of the P2X<sub>7</sub>R as an effective therapeutic target. Whether inhibition of P2X<sub>7</sub>Rs has beneficial or harmful effects on

brain ischemic injury and whether P2X<sub>7</sub>R over-expression drives microglial activation or, conversely, P2X<sub>7</sub>R over-expression is a consequence of microglial activation are still not known. The activation of P2X<sub>7</sub>Rs to induce neuroinflammation acts as a double-edged sword none the less. Further investigations to discover novel, potent, and more selective P2X<sub>7</sub>R antagonists will be critical to evaluate this target's potential therapeutic use, and may provide novel tools both for clinical and research purposes.

## ACKNOWLEDGEMENTS

This review was supported by a grant from the Natural Science Foundation of Liaoning Province, China (201202050).

Received date: 2012-07-09; Accepted date: 2012-10-16

## REFERENCES

- [1] Franke H, Gunther A, Grosche J, Schmidt R, Rossner S, Reinhardt R, *et al.* P2X<sub>7</sub> receptor expression after ischemia in the cerebral cortex of rats. *J Neuropathol Exp Neurol* 2004, 63: 686–699.
- [2] Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. *Nat Rev Neurosci* 2006, 7: 423–436.
- [3] Sperlagh B, Vizi ES, Wirkner K, Illes P. P2X<sub>7</sub> receptors in the nervous system. *Prog Neurobiol* 2006, 78: 327–346.
- [4] Melani A, Amadio S, Gianfriddo M, Vannucchi MG, Volonte C, Bernardi G, *et al.* P2X<sub>7</sub> receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat. *J Cereb Blood Flow Metab* 2006, 26: 974–982.
- [5] North RA. Molecular physiology of P2X receptors. *Physiol Rev* 2002, 82: 1013–1067.
- [6] Surprenant A, North RA. Signaling at purinergic P2X receptors. *Annu Rev Physiol* 2009, 71: 333–359.
- [7] Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, *et al.* P2X<sub>7</sub> receptor signaling pathway as a therapeutic target for neurodegenerative diseases. *Arch Immunol Ther Exp (Warsz)* 2010, 58: 91–96.
- [8] Skaper SD, Debetto P, Giusti P. The P2X<sub>7</sub> purinergic receptor: from physiology to neurological disorders. *FASEB J* 2010, 24: 337–345.
- [9] Arbeloa J, Perez-Samartin A, Gottlieb M, Matute C. P2X<sub>7</sub> receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. *Neurobiol Dis* 2012, 45: 954–961.
- [10] Friedle SA, Curet MA, Watters JJ. Recent patents on novel P2X<sub>7</sub> receptor antagonists and their potential for reducing

- central nervous system inflammation. *Recent Pat CNS Drug Discov* 2010, 5: 35–45.
- [11] Cavaliere F, Amadio S, Sancesario G, Bernardi G, Volonte C. Synaptic P2X<sub>7</sub> and oxygen/glucose deprivation in organotypic hippocampal cultures. *J Cereb Blood Flow Metab* 2004, 24: 392–398.
- [12] Le Feuvre RA, Brough D, Touzani O, Rothwell NJ. Role of P2X<sub>7</sub> receptors in ischemic and excitotoxic brain injury *in vivo*. *J Cereb Blood Flow Metab* 2003, 23: 381–384.
- [13] Yanagisawa D, Kitamura Y, Takata K, Hide I, Nakata Y, Taniguchi T. Possible involvement of P2X<sub>7</sub> receptor activation in microglial neuroprotection against focal cerebral ischemia in rats. *Biol Pharm Bull* 2008, 31: 1121–1130.
- [14] Wang LY, Cai WQ, Chen PH, Deng QY, Zhao CM. Downregulation of P2X<sub>7</sub> receptor expression in rat oligodendrocyte precursor cells after hypoxia ischemia. *Glia* 2009, 57: 307–319.
- [15] Virginio C, MacKenzie A, North RA, Surprenant A. Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X<sub>7</sub> receptor. *J Physiol* 1999, 519 (Pt 2): 335–346.
- [16] Monif M, Burnstock G, Williams DA. Microglia: proliferation and activation driven by the P2X<sub>7</sub> receptor. *Int J Biochem Cell Biol* 2010, 42: 1753–1756.
- [17] Adinolfi E, Pizzirani C, Idzko M, Panther E, Norgauer J, Di Virgilio F, *et al.* P2X<sub>7</sub> receptor: Death or life? *Purinergic Signal* 2005, 1: 219–227.
- [18] Anderson CM, Nedergaard M. Emerging challenges of assigning P2X<sub>7</sub> receptor function and immunoreactivity in neurons. *Trends Neurosci* 2006, 29: 257–262.
- [19] Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, *et al.* International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. *Pharmacol Rev* 2001, 53: 107–118.
- [20] Monif M, Reid CA, Powell KL, Smart ML, Williams DA. The P2X<sub>7</sub> receptor drives microglial activation and proliferation: a trophic role for P2X<sub>7</sub>R pore. *J Neurosci* 2009, 29: 3781–3791.
- [21] Wirkner K, Kofalvi A, Fischer W, Gunther A, Franke H, Groger-Arndt H, *et al.* Supersensitivity of P2X receptors in cerebrocortical cell cultures after *in vitro* ischemia. *J Neurochem* 2005, 95: 1421–1437.
- [22] Wang X, Arcuino G, Takano T, Lin J, Peng WG, Wan P, *et al.* P2X<sub>7</sub> receptor inhibition improves recovery after spinal cord injury. *Nat Med* 2004, 10: 821–827.
- [23] Melani A, Turchi D, Vannucchi MG, Cipriani S, Gianfriddo M, Pedata F. ATP extracellular concentrations are increased in the rat striatum during *in vivo* ischemia. *Neurochem Int* 2005, 47: 442–448.
- [24] Le Feuvre R, Brough D, Rothwell N. Extracellular ATP and P2X<sub>7</sub> receptors in neurodegeneration. *Eur J Pharmacol* 2002, 447: 261–269.
- [25] Milius D, Sperlagh B, Illes P. Up-regulation of P2X<sub>7</sub> receptor-immunoreactivity by *in vitro* ischemia on the plasma membrane of cultured rat cortical neurons. *Neurosci Lett* 2008, 446: 45–50.
- [26] Duan S, Anderson CM, Keung EC, Chen Y, Swanson RA. P2X<sub>7</sub> receptor-mediated release of excitatory amino acids from astrocytes. *J Neurosci* 2003, 23: 1320–1328.
- [27] Zeng W, Tong Y, Li H, Luo R, Mao M. P2X<sub>7</sub> receptor modulation of the viability of radial glial clone L2.3 cells during hypoxic-ischemic brain injury. *Mol Med Report* 2012, 5: 1357–1361.
- [28] Nakanishi M, Mori T, Nishikawa K, Sawada M, Kuno M, Asada A. The effects of general anesthetics on P2X<sub>7</sub> and P2Y receptors in a rat microglial cell line. *Anesth Analg* 2007, 104: 1136–1144.
- [29] Takenouchi T, Iwamaru Y, Sugama S, Sato M, Hashimoto M, Kitani H. Lysophospholipids and ATP mutually suppress maturation and release of IL-1 beta in mouse microglial cells using a Rho-dependent pathway. *J Immunol* 2008, 180: 7827–7839.
- [30] Yu Y, Ugawa S, Ueda T, Ishida Y, Inoue K, Kyaw Nyunt A, *et al.* Cellular localization of P2X<sub>7</sub> receptor mRNA in the rat brain. *Brain Res* 2008, 1194: 45–55.
- [31] Atkinson L, Milligan CJ, Buckley NJ, Deuchars J. An ATP-gated ion channel at the cell nucleus. *Nature* 2002, 420: 42.
- [32] Frizzo JK, Cardoso MP, de Assis AM, Perry ML, Volonte C, Frizzo ME. Effects of acute perinatal asphyxia in the rat hippocampus. *Cell Mol Neurobiol* 2010, 30: 683–692.
- [33] Lee M, Lee SJ, Choi HJ, Jung YW, Frokier J, Nielsen S, *et al.* Regulation of AQP4 protein expression in rat brain astrocytes: role of P2X<sub>7</sub> receptor activation. *Brain Res* 2008, 1195: 1–11.
- [34] Cavaliere F, Dinkel K, Reymann K. Microglia response and P2 receptor participation in oxygen/glucose deprivation-induced cortical damage. *Neuroscience* 2005, 136: 615–623.
- [35] Cavaliere F, D'Ambrosi N, Ciotti MT, Mancino G, Sancesario G, Bernardi G, *et al.* Glucose deprivation and chemical hypoxia: neuroprotection by P2 receptor antagonists. *Neurochem Int* 2001, 38: 189–197.
- [36] Skaper SD. Ion channels on microglia: therapeutic targets for neuroprotection. *CNS Neurol Disord Drug Targets* 2011, 10: 44–56.
- [37] Boucsein C, Zacharias R, Farber K, Pavlovic S, Hanisch UK, Kettenmann H. Purinergic receptors on microglial cells: functional expression in acute brain slices and modulation of microglial activation *in vitro*. *Eur J Neurosci* 2003, 17: 2267–2276.
- [38] Pellegatti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F. A novel recombinant plasma membrane-targeted luciferase

- reveals a new pathway for ATP secretion. *Mol Biol Cell* 2005, 16: 3659–3665.
- [39] Browne LE, Jiang LH, North RA. New structure enlivens interest in P2X receptors. *Trends Pharmacol Sci* 2010, 31: 229–237.
- [40] Kharlamov A, Jones SC, Kim DK. Suramin reduces infarct volume in a model of focal brain ischemia in rats. *Exp Brain Res* 2002, 147: 353–359.
- [41] Cavaliere F, Amadio S, Dinkel K, Reymann KG, Volonte C. P2 receptor antagonist trinitrophenyl-adenosine-triphosphate protects hippocampus from oxygen and glucose deprivation cell death. *J Pharmacol Exp Ther* 2007, 323: 70–77.
- [42] Sperlagh B, Zsilla G, Baranyi M, Illes P, Vizi ES. Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus. *Neuroscience* 2007, 149: 99–111.
- [43] Runden-Pran E, Tanso R, Haug FM, Ottersen OP, Ring A. Neuroprotective effects of inhibiting N-methyl-D-aspartate receptors, P2X receptors and the mitogen-activated protein kinase cascade: a quantitative analysis in organotypical hippocampal slice cultures subjected to oxygen and glucose deprivation. *Neuroscience* 2005, 136: 795–810.
- [44] Bano D, Nicotera P.  $\text{Ca}^{2+}$  signals and neuronal death in brain ischemia. *Stroke* 2007, 38: 674–676.
- [45] Csordas G, Hajnoczky G. SR/ER-mitochondrial local communication: calcium and ROS. *Biochim Biophys Acta* 2009, 1787: 1352–1362.
- [46] Iwabuchi S, Kawahara K. Functional significance of the negative-feedback regulation of ATP release via pannexin-1 hemichannels under ischemic stress in astrocytes. *Neurochem Int* 2011, 58: 376–384.
- [47] Lu YM, Tao RR, Huang JY, Li LT, Liao MH, Li XM, *et al.* P2X7 signaling promotes microsphere embolism-triggered microglia activation by maintaining elevation of Fas ligand. *J Neuroinflammation* 2012, 9: 172.
- [48] Faustino JV, Wang X, Johnson CE, Klibanov A, Derugin N, Wendland MF, *et al.* Microglial cells contribute to endogenous brain defenses after acute neonatal focal stroke. *J Neurosci* 2011, 31: 12992–13001.
- [49] Skaper SD, Facci L, Culbert AA, Evans NA, Chessell I, Davis JB, *et al.* P2X(7) receptors on microglial cells mediate injury to cortical neurons *in vitro*. *Glia* 2006, 54: 234–242.
- [50] Suzuki T, Hide I, Ido K, Kohsaka S, Inoue K, Nakata Y. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. *J Neurosci* 2004, 24: 1–7.
- [51] Chu K, Yin B, Wang J, Peng G, Liang H, Xu Z, *et al.* Inhibition of P2X7 receptor ameliorates transient global cerebral ischemia/reperfusion injury via modulating inflammatory responses in the rat hippocampus. *J Neuroinflammation* 2012, 9: 69.
- [52] Takenouchi T, Iwamaru Y, Sugama S, Tsukimoto M, Fujita M, Sekigawa A, *et al.* The activation of P2X7 receptor induces cathepsin D-dependent production of a 20-kDa form of IL-1 $\beta$  under acidic extracellular pH in LPS-primed microglial cells. *J Neurochem* 2011, 117: 712–723.
- [53] Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. *Annu Rev Immunol* 2009, 27: 519–550.
- [54] Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M, *et al.* Astrocyte-derived ATP induces vesicle shedding and IL-1  $\beta$  release from microglia. *J Immunol* 2005, 174: 7268–7277.
- [55] Takenouchi T, Fujita M, Sugama S, Kitani H, Hashimoto M. The role of the P2X7 receptor signaling pathway for the release of autolysosomes in microglial cells. *Autophagy* 2009, 5: 723–724.
- [56] Sperlagh B, Kofalvi A, Deuchars J, Atkinson L, Milligan CJ, Buckley NJ, *et al.* Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. *J Neurochem* 2002, 81: 1196–1211.
- [57] Lo JC, Huang WC, Chou YC, Tseng CH, Lee WL, Sun SH. Activation of P2X(7) receptors decreases glutamate uptake and glutamine synthetase activity in RBA-2 astrocytes via distinct mechanisms. *J Neurochem* 2008, 105: 151–164.
- [58] Matute C. Glutamate and ATP signalling in white matter pathology. *J Anat* 2011, 219: 53–64.
- [59] Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. *Trends Neurosci* 2009, 32: 19–29.
- [60] Beigi RD, Kertesz SB, Aquilina G, Dubyak GR. Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. *Br J Pharmacol* 2003, 140: 507–519.
- [61] Sikora A, Liu J, Brosnan C, Buell G, Chessell I, Bloom BR. Cutting edge: purinergic signaling regulates radical-mediated bacterial killing mechanisms in macrophages through a P2X7-independent mechanism. *J Immunol* 1999, 163: 558–561.
- [62] Choi HB, Ryu JK, Kim SU, McLarnon JG. Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain. *J Neurosci* 2007, 27: 4957–4968.
- [63] Yan XB, Meng FJ, Song B, Zhang GY. Brain ischemia induces serine phosphorylation of neuronal nitric oxide synthase by  $\text{Ca}^{2+}$ /calmodulin-dependent protein kinase II in rat hippocampus. *Acta Pharmacol Sin* 2004, 25: 617–622.
- [64] Alloisio S, Cervetto C, Passalacqua M, Barbieri R, Maura G, Nobile M, *et al.* Functional evidence for presynaptic P2X7 receptors in adult rat cerebrocortical nerve terminals. *FEBS Lett* 2008, 582: 3948–3953.
- [65] Zhang Y, Deng P, Li Y, Xu ZC. Enhancement of excitatory synaptic transmission in spiny neurons after transient forebrain ischemia. *J Neurophysiol* 2006, 95: 1537–1544.